Drug · CHEMBL1422
SITAGLIPTIN
7 sourcespipelines-2026-09-18-0.3.1
Cite this record
ConductScience Library. SITAGLIPTIN. Drugs and targets, record CHEMBL1422. Release pipelines-2026-09-18-0.3.1, 18 Sept 2026. https://conductscience.org/library/drugs/CHEMBL1422
On this page
Drug
Names and IDs as ChEMBL gives them, through Open Targets.
- Open Targets' highest stage
- Approval, for 2 of its 50 diseases, from ATC, EMA Human Drugs and TTD
- Open Targets
Targets1
The targets ChEMBL's mechanism records give for the drug, through Open Targets. A mechanism record says what the drug acts on, not how strongly.
| Target | Protein | Mechanism | Action | Gene in Genes |
|---|---|---|---|---|
| DPP4 | Dipeptidyl peptidase 4 | Dipeptidyl peptidase IV inhibitor | INHIBITOR | https://conductscience.org/library/genes/1803 |
Source ChEMBL
Diseases50
The diseases Open Targets' clinical reports study the drug for, the most trial reports first. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.
| Disease | Open Targets' stage | Stage reported by | Reports | Of them trials | Its drugs |
|---|---|---|---|---|---|
| type 2 diabetes mellitus | Approval | EMA Human Drugs and TTD | 277 | 262 | https://conductscience.org/library/drugs?q=MONDO_0005148 |
| diabetes mellitus | Approval | ATC | 15 | 13 | https://conductscience.org/library/drugs?q=MONDO_0005015 |
| type 1 diabetes mellitus | Phase 3 | ClinicalTrials.gov | 9 | 9 | https://conductscience.org/library/drugs?q=MONDO_0005147 |
| chronic kidney disease | Phase 3 | ClinicalTrials.gov | 4 | 4 | https://conductscience.org/library/drugs?q=MONDO_0005300 |
| hypertensive disorder | Early phase 1 | ClinicalTrials.gov | 4 | 4 | https://conductscience.org/library/drugs?q=MONDO_0005044 |
| HIV infectious disease | Phase 3 | ClinicalTrials.gov | 3 | 3 | https://conductscience.org/library/drugs?q=MONDO_0005109 |
| Impaired glucose tolerance | Phase 2 | ClinicalTrials.gov | 3 | 3 | https://conductscience.org/library/drugs?q=HP_0040270 |
| Insulin resistance | Phase 3 | ClinicalTrials.gov | 3 | 3 | https://conductscience.org/library/drugs?q=HP_0000855 |
| metabolic dysfunction-associated steatohepatitis | Phase 2 | ClinicalTrials.gov | 3 | 3 | https://conductscience.org/library/drugs?q=MONDO_0007027 |
| myocardial infarction | Unknown | ClinicalTrials.gov | 3 | 3 | https://conductscience.org/library/drugs?q=MONDO_0005068 |
1 to 10 of 50Source Open Targets
See all 50 diseasesTrials435
Trials whose record names the drug by a name ChEMBL states, posted results first, then the largest. Open Targets read each trial's text to find its drugs. 1 more that Open Targets linked to it is not shown, since the release's checks do not confirm it.
| Trial | Title | Phase | Participants | Results first posted | Named as | Linked by | Source |
|---|---|---|---|---|---|---|---|
| NCT00790205 | Sitagliptin Cardiovascular Outcomes Study (MK-0431-082) | Phase 3 | 14,671 | 2016-04-15 | sitagliptin | Its name | ClinicalTrials.gov |
| NCT01794143 | A Comparative Effectiveness Study of Major Glycemia-lowering Medications for Treatment of Type 2 Diabetes | Phase 3 | 7,850 | 2026-02-10 | sitagliptin | Its name | ClinicalTrials.gov |
| NCT01289990 | Safety and Efficacy of Empagliflozin (BI 10773) and Sitagliptin Versus Placebo Over 76 Weeks in Patients With Type 2 Diabetes | Phase 3 | 2,705 | 2014-07-15 | sitagliptin | Its name | ClinicalTrials.gov |
| NCT02607865 | Efficacy and Long-term Safety of Oral Semaglutide Versus Sitagliptin in Subjects With Type 2 Diabetes | Phase 3 | 1,864 | 2020-02-27 | sitagliptin | Its name | ClinicalTrials.gov |
| NCT00722371 | MK0431 and Pioglitazone Co-Administration Factorial Study in Patients With Type 2 Diabetes Mellitus (0431-102 AM2) | Phase 3 | 1,615 | 2011-10-17 | sitagliptin | Its name | ClinicalTrials.gov |
| NCT04017832 | A Research Study Comparing a New Medicine Oral Semaglutide to Sitagliptin in People With Type 2 Diabetes | Phase 3 | 1,441 | 2023-09-29 | sitagliptin | Its name | ClinicalTrials.gov |
| NCT01106677 | The CANTATA-D Trial (CANagliflozin Treatment and Trial Analysis - DPP-4 Inhibitor Comparator Trial) | Phase 3 | 1,284 | 2013-07-30 | sitagliptin | Its name | ClinicalTrials.gov |
| NCT02099110 | Ertugliflozin and Sitagliptin Co-administration Factorial Study (VERTIS FACTORAL, MK-8835-005) | Phase 3 | 1,233 | 2017-11-01 | sitagliptin | Its name | ClinicalTrials.gov |
| NCT01930188 | Efficacy and Safety of Semaglutide Once-weekly Versus Sitagliptin Once-daily as add-on to Metformin and/or TZD in Subjects With Type 2 Diabetes | Phase 3 | 1,231 | 2019-01-07 | sitagliptin | Its name | ClinicalTrials.gov |
| NCT00103857 | MK0431 (Sitagliptin) and Metformin Co-Administration Factorial Study in Patients With Type 2 Diabetes Mellitus (0431-036) | Phase 3 | 1,208 | 2009-05-19 | sitagliptin | Its name | ClinicalTrials.gov |
1 to 10 of 435
See all 435 trialsComparisons in its trials208
Comparisons Trial comparisons calculated in the trials whose record names the drug, most participants first. A comparison in one of its trials does not always compare the drug, so read the two groups.
| Comparison | Group 1, with the outcome | Group 2, with the outcome | Participants | Trial | Source |
|---|---|---|---|---|---|
| Sitagliptin vs Placebo: serious adverse events | 928 of 7,266 | 909 of 7,274 | 14,540 | NCT00790205 | Trial comparisons |
| Sitagliptin 100 mg vs Glipizide: Number of Participants With Drug-related LAEs at Week 104 | 18 of 588 | 21 of 584 | 1,172 | NCT00094770 | Trial comparisons |
| Sitagliptin 100 mg vs Glipizide: serious adverse events | 64 of 588 | 73 of 584 | 1,172 | NCT00094770 | Trial comparisons |
| Sitagliptin vs Glimepiride: serious adverse events | 16 of 516 | 11 of 518 | 1,034 | NCT00701090 | Trial comparisons |
| Sitagliptin vs Sulfonylurea: serious adverse events | 0 of 507 | 3 of 514 | 1,021 | NCT01131182 | Trial comparisons |
| Sitagliptin vs Sulfonylurea Therapy: serious adverse events | 1 of 421 | 0 of 427 | 848 | NCT01340768 | Trial comparisons |
| Saxa + Met vs Sita + Met: serious adverse events | 7 of 403 | 5 of 398 | 801 | NCT00666458 | Trial comparisons |
| Canagliflozin 300 mg vs Sitagliptin 100 mg: serious adverse events | 24 of 377 | 21 of 378 | 755 | NCT01137812 | Trial comparisons |
| Sitagliptin vs Placebo: deaths from any cause | 0 of 373 | 2 of 370 | 743 | NCT02738879 | Trial comparisons |
| Sitagliptin vs Placebo: serious adverse events | 14 of 373 | 18 of 370 | 743 | NCT02738879 | Trial comparisons |
1 to 10 of 208
See all 208 comparisons in its trialsPapers from its trials432
The papers the trials whose record names the drug list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.
Tests in its trials0
The tests ConductCognition runs that the trials whose record names the drug name in their registered outcomes, as ScienceGraph matched them. ConductCognition's list names the tests it runs, not every test a trial used.
None in this release.
Data dates
The date of each source this release read.
Sources 7
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ConductCognition's list of its testsOur own data
- ClinicalTrials.govNo license stated
- NLM's MeSHNLM's terms
- Open TargetsCC0 1.0
- PubMedNLM's terms
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ConductCognition's list of its testsOur own data: ConductCognition's list of its tests, https://conductcognition.com
- ClinicalTrials.govnone stated
- NLM's MeSHNLM's
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this drug from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/drugs/v1/CHEMBL1422
GET https://conductscience.org/api/drugs/v1/CHEMBL1422/diseases?page=2